COMMUNIQUÉS West-GlobeNewswire

Bone Biologics Improves Extension of rhNELL-1 Product Shelf Life to 24 Months
23/12/2025
Milestone advances manufacturing readiness and supports long-term commercialization strategy BURLINGTON, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ: [...]
Reviva Announces Regulatory Update Regarding the Development of Brilaroxazine for the Treatment of Schizophrenia
23/12/2025
Written feedback from FDA pre-NDA meeting includes a recommendation to conduct a second Phase 3 trial to generate additional efficacy and safety data prior to NDA submission of brilaroxazine for the treatment of [...]
Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026
23/12/2025
NEW YORK, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that it will [...]
LIXTE and its Collaborators Expand Clear Cell Ovarian Cancer Trial
23/12/2025
--Plans to double the Number of Patients in Study-- --Company Expects Initial Findings to be presented in 2026-- BOCA RATON, Fla., Dec. 23, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “ [...]
Trinity Biotech Awarded a Major Order for 9 Million TrinScreen HIV Tests
23/12/2025
- TrinScreen HIV order signals renewed strength in global HIV testing market - Company also reports a key milestone of Adjusted EBITDA 1 positive operations in Q3 2025 and expects to achieve strong additional [...]
Avicanna Announces Changes to its Board of Directors
23/12/2025
TORONTO, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“ Avicanna ” or “ Company” ) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization [...]
Dyne Therapeutics Appoints Vikram Karnani to Board of Directors
23/12/2025
WALTHAM, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular [...]
Glucose Health, Inc. Completes Preferred Stock Conversion at an 85% Premium Positioning Company for Rapid Growth
23/12/2025
BENTONVILLE, Ark., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Glucose Health, Inc. (OTC: GLUC), a consumer-health company specializing in soluble-fiber nutrition products for metabolic support, today announced the completion of [...]
Invivyd Earns Fast Track Designation for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID
23/12/2025
NEW HAVEN, Conn., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for VYD2311, an investigational [...]
Invivyd Announces Initiation of DECLARATION Clinical Trial, a Phase 3 Placebo-Controlled Pivotal Study of VYD2311, a Vaccine-Alternative Antibody to Prevent COVID
23/12/2025
DECLARATION is a Phase 3, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of VYD2311 in the prevention of COVID versus placebo, at three months, from a single intramuscular (IM) dose, [...]
Secura Bio Announces Participation in Gilmartin Group’s 2026 Corporate Access Event in San Francisco
23/12/2025
BERKELEY HEIGHTS, N.J., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Secura Bio, Inc. ( www.securabio.com ), an integrated pharmaceutical company dedicated to the worldwide development and commercialization of impactful oncology [...]
LAPIX Therapeutics Announces First Patient Dosed in Phase Ib Study of LPX-TI641 in Atopic Dermatitis
23/12/2025
Study Evaluates New Oral Capsule Formulation in a Th2-Dominant Inflammatory Disease CAMBRIDGE, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- LAPIX Therapeutics, Inc. (“LAPIX”), a clinical-stage biopharmaceutical company [...]
AtaiBeckley Added to the Nasdaq Biotechnology Index (NBI)
23/12/2025
NEW YORK and AMSTERDAM, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Atai Beckley N.V. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by [...]
Leads Biolabs And Dianthus Therapeutics Announce Initiation of Phase 1 Trial Of LBL-047 (DNTH212) In Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE)
23/12/2025
LBL-047 (DNTH212) is a bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function Top- [...]
Best Sermorelin Tablet for 2026? bmiMD Platform Lists Mint Sublingual Format at $79/Month as Peptide Wellness Interest Surges Before New Year
23/12/2025
Needle-Free Growth Hormone Support via Telehealth — Platform Analysis Compares Compounded Prescription Tablets vs. Injectable Format as Consumer Search Volume for "Sermorelin Alternative" Climbs 340% Year-Over-Year NEW [...]
Best GLP-1 Gummies for 2026: Akkermansia Probiotic Supplements for Weight Loss – Industry Analysis
23/12/2025
Analysis Examines GlucoBooster GLP-1 Gummies and Akkermansia-Based Probiotic Category Ahead of 2026 Weight-Loss Season – Ingredient Research, Regulatory Context, and Evidence Gaps Explained New York, Dec. 22, 2025 ( [...]
Novo Nordisk A/S: Wegovy® pill approved in the US as first oral GLP-1 for weight management
22/12/2025
Wegovy ® pill showed a mean weight loss of 16.6% in the OASIS 4 trial 1 Wegovy ® pill is indicated to reduce excess body weight and maintain weight reduction long-term and to reduce the risk of major adverse [...]
RxSight, Inc. Announces Chief Financial Officer Transition
22/12/2025
ALISO VIEJO, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced [...]
Apollomics Reports First Half 2025 Financial Results
22/12/2025
FOSTER CITY, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM ) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to [...]

Pages